Combination of sildenafil and bosentan for nitric oxide withdrawal.
Behrends
M
M
Beiderlinden
M
M
Peters
J
J
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009569:Nitric Oxide / Q000009:adverse effects*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D012128:Respiratory Distress Syndrome / Q000150:complications / Q000188:drug therapy; D000068677:Sildenafil Citrate; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015300:Ventilator Weaning
D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D000077300:Bosentan